Stock Price Forecast

June 1, 2022


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Genocea Biosciences Inc chart...

About the Company

Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.

CEO

William Clark

Exchange

NASDAQ

Website

www.genocea.com

$2M

Total Revenue

72

Employees

$4M

Market Capitalization

-0.12

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $GNCA News

Genocea Biosciences – a Good Buy and Hold Stock

19h ago, source: FXEmpire.com

Here is one example currently running on my personal account. Recently, I bought 4,000 shares of Genocea Biosciences, Inc., (NASDAQ: GNCA). This company is listed in the Healthcare sector and ...

Genocea Biosciences Inc 0A51

22d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Genocea Biosciences, Inc. (GNCAQ)

1y ago, source: Yahoo Finance

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Genocea Bio (GNCAQ) Earnings Dates & Reports

7mon ago, source: Investing

View upcoming earnings forecasts and in-depth analysis of company forecasts.

Lux Venture Partners II, L.P.'s Net Worth

1mon ago, source: Benzinga.com

This is based on reported shares across multiple companies, which include GENOCEA BIOSCIENCES, INC., Cerulean Pharma Inc., EVERSPIN TECHNOLOGIES INC, and Kala Pharmaceuticals, Inc.. Attention ...

Lux Capital Management, LLC's Net Worth

18d ago, source: Benzinga.com

This is based on reported shares across multiple companies, which include GENOCEA BIOSCIENCES, INC., Cerulean Pharma Inc., EVERSPIN TECHNOLOGIES INC, Kala Pharmaceuticals, Inc., and Science 37 ...

Assembly Biosciences Inc ASMB

5d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Pacira BioSciences Inc.

4d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Forte Biosciences Inc.

8mon ago, source: CNN

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The firm's lead product includes FB-401, which is a live biotherapeutic ...

CTKB Cytek Biosciences, Inc.

3d ago, source: Seeking Alpha

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and ...

Castle Biosciences, Inc. (NASDAQ:CSTL): Are Analysts Optimistic?

18d ago, source: Yahoo Finance

With the business potentially at an important milestone, we thought we'd take a closer look at Castle Biosciences, Inc.'s (NASDAQ:CSTL) future prospects. Castle Biosciences, Inc., a commercial ...

SNTI Senti Biosciences, Inc.

6d ago, source: Seeking Alpha

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...